Market Revenue Human Growth Hormone Drugs Industry | Page 2

The growth hormone is medically stated to be somatotropin. When pituitary gland malfunctions, it either
secretes less HGH than required or more than required on account of which in cases of less secretion there is
restriction of growth in the body, organs and limbs which will lead to dwarfism, while in case of more than
required secretion there is excess growth in limbs and peripheral abnormalities arise which lead to gigantism,
disfiguration in the body parts including, face and feet.
The major trends which include continuous increase of recombinant growth hormones industry and increasing
use of bio-similar drugs and an agreement for long acting (HGH-CTP) human growth hormone. On the industry
development front, the current inclination is towards developing needle free injections technology and better
treatments for Alzheimer's disease. In addition, the major factors driving the HGH industry include rising cancer,
CKD and ESRD cases and increase in healthcare expenditure on a global level in past few years. Factors which
are expected to pose challenge to the industry include the issues in diagnosis of HGH deficiency, hazards
associated with the usage of recombinant growth hormone therapies and use of HGH without label, to a certain
level, are expected to hinder the growth and development of the product industry.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/human-growth-hormone-drugs-market
The segmentation of the market includes the market for treatment of growth hormone deficiency in adults and
children and the vanity sector which uses the growth hormone for enhancing the body performance, however,
FDA does not recommend these uses hence they are less worthwhile. The malformations in the pituitary and
abnormalities in the growth hormone secretion levels majorly impacts children and teenagers worldwide.
Therefore, there are a large number of consumers who need the drugs which treat growth hormone related
health issues for children and adults.
The pharmaceutical industry is being allocated with a lot of funds for research and development for the
betterment of drugs related to growth hormone which offer greater sustained release and longer action periods.
The growth of this sector is also fuelled on account of the modernization in the methods of delivery of the
hormones. The prescription products including Saizen, Humatrope, Genotropin and Norditropin are highly
sought and viable for therefore having a higher price.
Europe is observed to be the dominating the industry from the past few years on account of excessive research
and development and technological advancements in the sector, followed by North America. The Asia Pacific
and China are expected to be the lucrative market for the product owing to the large population. The major
market players operating in the market include Pfizer,